卵巢癌新辅助化疗后血清CA125变化及CT检查对肿瘤细胞减灭术疗效的预测价值  

Changes in Erum CA125 after Neoadjuvant Chemotherapy for Ovarian Cancer and the Predictive Value of CT Examination for the Efficacy of Cytoreductive Surgery

作　　者：田翔宇 牛家成[1] 姚淑娟 崔秀娟[3] 王稳[3] TIAN Xiangyu;NIU Jiacheng;YAO Shujuan;CUI Xiujuan;WANG Wen(Medical Imaging Center of Tengzhou Central People's Hospital in Shandong Province,Tengzhou 277599,China;Obstetrics and Gynecology Department of Shandong University of Traditional Chinese Medicine Affiliated Hospital,Jinan 250011,China;Department of Obstetrics and Gynecology,Tengzhou Central People's Hospital,Tengzhou 277599,China)

机构地区：[1]山东省滕州市中心人民医院医学影像中心,山东滕州277599 [2]山东中医药大学附属医院妇产科,山东济南250013 [3]山东省滕州市中心人民医院妇一科,山东滕州277599

出　　处：《中华灾害救援医学》2024年第3期260-262,270,共4页Chinese Journal of Disaster Medicine

基　　金：山东省医药卫生科技发展计划项目(2018WSA04019)。

摘　　要：目的利用CA125水平和CT检查,预测卵巢癌患者新辅助化疗联合肿瘤细胞减灭术的疗效。方法选择2021年7月至2023年7月于滕州市中心人民医院就诊的经病理确诊为上皮性卵巢癌68例患者为研究对象,所有患者均先采取铂类与紫杉醇的新辅助化疗,后进行肿瘤细胞减灭术。分析患者的一般资料、CA125水平与肿瘤细胞减灭术满意度之间的关系、化疗疗效、术前CT检查Jonathan评分与肿瘤细胞减灭术满意度比较。结果分为手术前血清CA125≤45U/ml和手术前血清CA125>45U/ml,组间肿瘤细胞减灭术满意度有明显差异(P=0.001);分为手术前血清CA125≤500U/ml和手术前血清CA125>500U/ml,组间肿瘤细胞减灭术满意度有明显差异(P=0.005);分为手术后血清CA125下降≥80%和手术后血清CA125下降<80%,组间肿瘤细胞减灭术满意度有明显差异(P=0.007);分为手术后血清CA125下降≥50%和手术后血清CA125下降<50%,组间肿瘤细胞减灭术满意度无明显差异(P=0.253)。经3个周期化疗后,CR患者0例(0.00%)、PR患者35例(51.47%)、SD患者27例(39.71%)、PD患者6例(8.82%)。术前Jonathan评分<3分组中48例患者对肿瘤细胞减灭术满意,满意率为96.00%,术前Jonathan评分≥3分组中6例患者对肿瘤细胞减灭术满意,满意率为33.33%,差异有统计学意义(P<0.001)。结论血清CA125变化及CT检查,可作为卵巢癌患者肿瘤细胞减灭疗效的预测手段,为患者手术时机的选择提供参考。Objective To evaluate the efficacy of using CA125 levels and CT scans to predict the efficacy of neoadjuvant chemotherapy combined with tumor cell reduction surgery in ovarian cancer patients.Methods patients diagnosed with epithelial ovarian cancer through pathological examination at Tengzhou Central People's Hospital from July 2021 to July 2023 were selected as the study subjects.All patients underwent neoadjuvant chemotherapy with platinum and paclitaxel before undergoing tumor cell reduction surgery.We analyze the general information of patients,the relationship between CA125 levels and satisfaction with tumor cell reduction surgery,chemotherapy efficacy,Jonathan's score on preoperative CT examination,and satisfaction with tumor cell reduction surgery.Results Comparingthe preoperative serum CA125≤45U/ml groupwiththe preoperative serum CA125>45U/ml group,there was a significant difference in satisfaction with tumor cell reduction surgery between the two groups(P=0.001);There was a significant difference in satisfaction with tumor cell reduction surgery between the two groups,when we comparedthe preoperative serum CA125≤500U/ml groupwiththe preoperative serum CA125>500U/ml group(P=0.005);There was a significant difference in satisfaction with tumor cell reduction surgery between the two groups,when we comparedthe decrease of≥80%in serum CA125 after surgery group and the decrease of<80%in serum CA125 after surgery group(P=0.007);There was no significant difference in satisfaction with tumor cell reduction surgery between the two groups,when we compared the decrease of≥50%in serum CA125 after surgery group and the decrease of<50%in serum CA125 after surgery group(P=0.253).After 3 cycles of chemotherapy,there were 0 CR patients(0.00%),35 PR patients(51.47%),27 SD patients(39.71%),and 6 PD patients(8.82%).48 patients in the preoperative Jonathan score<3 groups were satisfied with tumor cell reduction surgery,with a satisfaction rate of 96.00%.In the preoperative Jonathan score≥3 groups,6 patients were sat

关 键 词：卵巢肿瘤 肿瘤治疗方案 体层摄影扫描仪 X线计算机 

分 类 号：R737.31[医药卫生—肿瘤]